Affymetrix Inc. (Nasdaq:AFFX) and the CureSearch Children’s Oncology Group (COG) announced today that they have entered into a collaboration to discover and validate gene expression signatures, or genetic fingerprints, for a number of common childhood cancers, including leukemia and sarcoma, a common solid tumor. The two organizations will work together using Affymetrix’ GeneChip(R) microarray technology and COG’s existing databank of more than 20,000 tumor samples.
